HRP20191480T1 - Liječenje neuropatije malih vlakana - Google Patents
Liječenje neuropatije malih vlakana Download PDFInfo
- Publication number
- HRP20191480T1 HRP20191480T1 HRP20191480TT HRP20191480T HRP20191480T1 HR P20191480 T1 HRP20191480 T1 HR P20191480T1 HR P20191480T T HRP20191480T T HR P20191480TT HR P20191480 T HRP20191480 T HR P20191480T HR P20191480 T1 HRP20191480 T1 HR P20191480T1
- Authority
- HR
- Croatia
- Prior art keywords
- pharmaceutically acceptable
- small fiber
- fiber neuropathy
- fluorophenyl
- oxy
- Prior art date
Links
- 208000010261 Small Fiber Neuropathy Diseases 0.000 title claims 8
- 206010073928 Small fibre neuropathy Diseases 0.000 title claims 8
- 208000017692 primary erythermalgia Diseases 0.000 claims 7
- 150000003839 salts Chemical class 0.000 claims 5
- JESCETIFNOFKEU-SJORKVTESA-N (2s,5r)-5-[4-[(2-fluorophenyl)methoxy]phenyl]pyrrolidine-2-carboxamide Chemical compound N1[C@H](C(=O)N)CC[C@@H]1C(C=C1)=CC=C1OCC1=CC=CC=C1F JESCETIFNOFKEU-SJORKVTESA-N 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 3
- 101150041164 Cacna1a gene Proteins 0.000 claims 1
- 101150060553 Cacna1b gene Proteins 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000007614 genetic variation Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Materials For Medical Uses (AREA)
- Artificial Filaments (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Claims (7)
1. (5R) -5- (4 - {[(2-Fluorofenil) metil] oksi} fenil) -L-prolinamid ili njegova farmaceutski prihvatljiva sol za uporabu u liječenju neuropatije malih vlakana.
2. Spoj za uporabu prema zahtjevu 1, naznačen time, da je (5R) -5- (4 - {[(2-fluorofenil) metil] oksi} fenil) -L-prolinamid ili njegova farmaceutski prihvatljiva sol je (5R) - Hidroklorid 5- (4 - {[(2-fluorofenil) metil] oksi} fenil) -L-prolinamid hidroklorid.
3. Farmaceutski pripravak, naznačen time što sadrži (5R) -5- (4 - {[(2-fluorofenil) metil] oksi} fenil) -L-prolinamid ili njegovu farmaceutski prihvatljivu sol za uporabu u liječenju neuropatije malih vlakana.
4. Pripravak za uporabu prema zahtjevu 3 ili njegova farmaceutski prihvatljiva sol, koji dodatno sadrži jedan ili više farmaceutski prihvatljivih nosača, razrjeđivača i / ili ekscipijenata.
5. (5R) -5- (4 - {[(2-Fluorofenil) metil] oksi} fenil) -L-prolinamid ili njegova farmaceutski prihvatljiva sol za uporabu u liječenju neuropatije malih vlakana kod pacijenta, naznačeno time što je navedeni pacijent odabran zbog toga što ima jednu ili više genetskih varijacija unutar gena CACNA1A i / ili gena CACNA1B.
6. Spoj ili pripravak za uporabu prema bilo kojem od zahtjeva 1 do 5, naznačen time, da je navedena neuropatija malih vlakana primarna neuropatija malih vlakana.
7. Spoj ili pripravak prema bilo kojem od zahtjeva 1 do 5, naznačen time, da je neuropatija malih vlakana sekundarna neuropatija malih vlakana.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1417499.9A GB201417499D0 (en) | 2014-10-03 | 2014-10-03 | Novel use |
| EP15790623.1A EP3200784B1 (en) | 2014-10-03 | 2015-10-02 | Small fibre neuropathy treatment |
| PCT/GB2015/052886 WO2016051195A1 (en) | 2014-10-03 | 2015-10-02 | Small fibre neuropathy treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20191480T1 true HRP20191480T1 (hr) | 2020-06-12 |
Family
ID=51946796
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20191480TT HRP20191480T1 (hr) | 2014-10-03 | 2019-08-16 | Liječenje neuropatije malih vlakana |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20170290802A1 (hr) |
| EP (1) | EP3200784B1 (hr) |
| CY (1) | CY1122769T1 (hr) |
| DK (1) | DK3200784T3 (hr) |
| ES (1) | ES2750355T3 (hr) |
| GB (1) | GB201417499D0 (hr) |
| HR (1) | HRP20191480T1 (hr) |
| HU (1) | HUE045907T2 (hr) |
| LT (1) | LT3200784T (hr) |
| PL (1) | PL3200784T3 (hr) |
| PT (1) | PT3200784T (hr) |
| RS (1) | RS59621B1 (hr) |
| SI (1) | SI3200784T1 (hr) |
| WO (1) | WO2016051195A1 (hr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3042384A1 (en) * | 2016-11-02 | 2018-05-11 | Biogen Ma Inc. | Novel dosage regimen |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO870613L (no) | 1986-03-05 | 1987-09-07 | Molecular Diagnostics Inc | Deteksjon av mikroorganismer i en prve inneholdende nukleinsyre. |
| AU632494B2 (en) | 1988-05-20 | 1993-01-07 | F. Hoffmann-La Roche Ag | Immobilized sequence-specific probes |
| US5118801A (en) | 1988-09-30 | 1992-06-02 | The Public Health Research Institute | Nucleic acid process containing improved molecular switch |
| US5210015A (en) | 1990-08-06 | 1993-05-11 | Hoffman-La Roche Inc. | Homogeneous assay system using the nuclease activity of a nucleic acid polymerase |
| WO1993022456A1 (en) | 1992-04-27 | 1993-11-11 | Trustees Of Dartmouth College | Detection of gene sequences in biological fluids |
| US5474995A (en) | 1993-06-24 | 1995-12-12 | Merck Frosst Canada, Inc. | Phenyl heterocycles as cox-2 inhibitors |
| US5538848A (en) | 1994-11-16 | 1996-07-23 | Applied Biosystems Division, Perkin-Elmer Corp. | Method for detecting nucleic acid amplification using self-quenching fluorescence probe |
| US5466823A (en) | 1993-11-30 | 1995-11-14 | G.D. Searle & Co. | Substituted pyrazolyl benzenesulfonamides |
| US5633272A (en) | 1995-02-13 | 1997-05-27 | Talley; John J. | Substituted isoxazoles for the treatment of inflammation |
| CA2212836C (en) | 1995-02-13 | 2003-08-12 | G.D. Searle & Co. | Substituted isoxazoles for the treatment of inflammation |
| UA57002C2 (uk) | 1995-10-13 | 2003-06-16 | Мерк Фросст Кенада Енд Ко./Мерк Фросст Кенада Енд Сі. | Похідне (метилсульфоніл)феніл-2-(5н)-фуранону, фармацевтична композиція та спосіб лікування |
| EP0892791B1 (en) | 1996-04-12 | 2003-03-05 | G.D. Searle & Co. | N-[[4-(5-METHYL-3-PHENYLISOXAZOL-4-YL]PHENYL]SULFONYLPROPYLAMIDE and its SODIUMSALT AS PRODRUGS OF COX-2 INHIBITORS |
| US5866336A (en) | 1996-07-16 | 1999-02-02 | Oncor, Inc. | Nucleic acid amplification oligonucleotides with molecular energy transfer labels and methods based thereon |
| US6117635A (en) | 1996-07-16 | 2000-09-12 | Intergen Company | Nucleic acid amplification oligonucleotides with molecular energy transfer labels and methods based thereon |
| DK0912518T3 (da) | 1996-07-18 | 2003-12-08 | Merck Frosst Canada Inc | Substituerede pyridiner som selektive cyclooxygenase-2 inhibitorer |
| CO4960662A1 (es) | 1997-08-28 | 2000-09-25 | Novartis Ag | Ciertos acidos 5-alquil-2-arilaminofenilaceticos y sus derivados |
| PL194557B1 (pl) | 1997-09-05 | 2007-06-29 | Glaxo Group Ltd | Pochodna 2,3-diarylopirazolo[1,5-b]pirydazyny, jej wytwarzanie, kompozycja farmaceutyczna zawierająca pochodną i jej zastosowanie |
| CN1263755C (zh) | 1998-11-03 | 2006-07-12 | 葛兰素集团有限公司 | 作为选择性cox－2抑制剂的吡唑并吡啶衍生物 |
| US6025683A (en) | 1998-12-23 | 2000-02-15 | Stryker Corporation | Motor control circuit for regulating a D.C. motor |
| DE69915519T2 (de) | 1999-02-27 | 2005-02-03 | Glaxo Group Ltd., Greenford | Pyrazolopyridine |
| GB0003224D0 (en) | 2000-02-11 | 2000-04-05 | Glaxo Group Ltd | Chemical compounds |
| GB0021494D0 (en) | 2000-09-01 | 2000-10-18 | Glaxo Group Ltd | Chemical comkpounds |
| TW200730494A (en) | 2005-10-10 | 2007-08-16 | Glaxo Group Ltd | Novel compounds |
-
2014
- 2014-10-03 GB GBGB1417499.9A patent/GB201417499D0/en not_active Ceased
-
2015
- 2015-10-02 SI SI201530864T patent/SI3200784T1/sl unknown
- 2015-10-02 ES ES15790623T patent/ES2750355T3/es active Active
- 2015-10-02 US US15/516,027 patent/US20170290802A1/en not_active Abandoned
- 2015-10-02 WO PCT/GB2015/052886 patent/WO2016051195A1/en active Application Filing
- 2015-10-02 DK DK15790623.1T patent/DK3200784T3/da active
- 2015-10-02 HU HUE15790623A patent/HUE045907T2/hu unknown
- 2015-10-02 EP EP15790623.1A patent/EP3200784B1/en active Active
- 2015-10-02 PT PT15790623T patent/PT3200784T/pt unknown
- 2015-10-02 LT LTEP15790623.1T patent/LT3200784T/lt unknown
- 2015-10-02 PL PL15790623T patent/PL3200784T3/pl unknown
- 2015-10-02 RS RS20191108A patent/RS59621B1/sr unknown
-
2019
- 2019-08-16 HR HRP20191480TT patent/HRP20191480T1/hr unknown
- 2019-10-31 CY CY20191101135T patent/CY1122769T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PL3200784T3 (pl) | 2020-03-31 |
| EP3200784B1 (en) | 2019-07-31 |
| CY1122769T1 (el) | 2021-05-05 |
| RS59621B1 (sr) | 2020-01-31 |
| GB201417499D0 (en) | 2014-11-19 |
| SI3200784T1 (sl) | 2020-03-31 |
| DK3200784T3 (da) | 2019-08-12 |
| ES2750355T3 (es) | 2020-03-25 |
| PT3200784T (pt) | 2019-09-10 |
| LT3200784T (lt) | 2019-09-10 |
| WO2016051195A1 (en) | 2016-04-07 |
| EP3200784A1 (en) | 2017-08-09 |
| HUE045907T2 (hu) | 2020-02-28 |
| US20170290802A1 (en) | 2017-10-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20201812T1 (hr) | Modulatori proteina jezgre hepatitisa b | |
| MA52709A (fr) | Administration d'adn | |
| MA47824A (fr) | Administration polyanionique d'acides nucléiques | |
| DK3364997T3 (da) | Aspartoacylase genterapi til behandling af canavans sygdom | |
| MA45539A (fr) | Dihydropyranopyrimidines pour le traitement d'infections virales | |
| PH12016501310A1 (en) | Pharmaceutical compositions comprising azd9291 | |
| WO2016109663A3 (en) | Derivatives and methods of treating hepatitis b infections | |
| BR112016007467A2 (pt) | compostos heterocíclicos e usos dos mesmos | |
| EA201792235A1 (ru) | Инъецируемые препараты замедленного высвобождения, содержащие изоксазолиновое действующее вещество, способы и применение | |
| CL2014002524A1 (es) | Composicion farmaceutica que comprende un compuesto activo de formula 1, antagonista de ccr3, dos diluyentes, un aglutinante, un desintegrante y un lubricante; formas de dosificacion en capsula, comprimido o comprimido recubierto con pelicula. | |
| HRP20191434T1 (hr) | Liječenje eritromelalgije | |
| WO2015051264A8 (en) | Epinephrine-based ophthalmic compositions for intraocular administration and methods for fabricating thereof | |
| MA43873A (fr) | Dspositif d'injection | |
| MX2019006768A (es) | Peptidos antimicrobianos. | |
| HRP20191480T1 (hr) | Liječenje neuropatije malih vlakana | |
| MA42611A (fr) | Traitement combiné comprenant l'administration de 2-amino-3,5,5-trifluoro-3,4,5,6-tétrahydropyridines | |
| DK3820849T3 (da) | Phenyl/pyridyl-nh-phenyl/pyridyl-derivater til behandling af rna-virusinfektion | |
| EA201692493A8 (ru) | Противомикробные фармацевтические композиции со способностями ингибирования множественной лекарственной устойчивости | |
| MA44859A (fr) | Pseudodimères d'oxazoline, compositions pharmaceutiques et utilisation correspondantes | |
| DK4021505T3 (da) | Medikament til behandling af infektionssygdomme | |
| BR112018000179A2 (pt) | composto, composição, e, método para tratar a infecção pelo hiv. | |
| BR112016029896A2 (pt) | métodos para o tratamento de infecções | |
| MA41620A (fr) | Composition pharmaceutique comprenant de la siméthicone et de l'otilonium | |
| UA35706S (uk) | Флакон для ін'єкційних розчинів | |
| UA35851S (uk) | Флакон для ін'єкційних розчинів |